November 3, 2021: We are concerned about the conflicting data on EVAR devices, and the reliance on 5-year studies that include different iterations of a device.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR’s Comments at EPA’s 2021 CHPAC Meeting
November 2, 2021: We strongly urge the EPA to conduct research on how currently used materials for artificial turf and playgrounds can pose risks to the health of the children who play on them, and to develop standards to regulate the safety of these materials.
Read More »NCHR’s Testimony on Carbetocin Nasal Spray for Hyperphagia in Prader Willi Syndrome
November 4, 2021. NCHR agrees with FDA criticisms of the evidence. Families urgently need help, but the company should spend a few more months to establish whether this drug is effective and safe for more than 8 weeks – BEFORE FDA considers approving it.
Read More »NCHR’s testimony about Endologix AFX endovascular graft system (EVAR) at the FDA Advisory Panel
November 2, 2021: The evidence does not support the use of the Endologix AFX EVAR devices, and the AFX2 device should not remain on the market while waiting for longer term data to determine if it is as safe as other EVAR devices.
Read More »NCHR Comments on AHRQ’s draft review on Maternal and Child Outcomes Associated with the Special Supplemental Nutrition Program
November 2, 2021: NCHR endorses the systematic review of WIC, an important program that aims to safeguard the health of low-income, nutritionally at-risk pregnant and postpartum women and children under the age of 5 years old.
Read More »